NeonMind
Appoints Ketamine
and Neurostimulation Expert Dr. Roumen Milev, MD, PhD
to Specialty Clinic Advisory Board
Company
Broadens Scientific Expertise with Addition of Mental
Health
Expert in
Setting Up and Managing Interventional Psychiatric
Clinics
Vancouver, B.C.
- September 16,
2021 -- InvestorsHub NewsWire -- NeonMind Biosciences
Inc. (CSE: NEON)
(OTCQB:
NMDBF)
(FRA:
6UF) ("NeonMind'' or the "Company"), an integrated drug development and
wellness company focused on the potential therapeutic uses of
psilocybin for treating obesity and weight management conditions,
announced today the appointment of Dr. Roumen Milev, MD, PhD,
Clinical Lead of Providence Care Hospital Interventional Psychiatry
to its Specialty Clinics Advisory Board. Providence Care Hospital
is one of Ontario's leading providers of specialized care in aging,
mental health, and rehabilitation and is fully affiliated with
Queen's University and St. Lawrence College, and an esteemed member
of the Council of Academic Hospitals of Ontario, Canada.
In his role on NeonMind's
Specialty Clinics Advisory Board, Dr. Milev will leverage his vast
experience and success in setting up and managing interventional
psychiatry clinics to support NeonMind as it develops its
company-branded, specialty clinics network to enhance access to
evidence-backed effective treatments including ketamine.
Dr. Milev leads the
Interventional Psychiatry Clinic at Providence Care Hospital in
Kingston, Ontario and has overseen more than 1,000 patients
successfully treated with ketamine and neurostimulation modalities.
He was appointed the Clinical Director of the Mood Disorder
Research and Treatment Service in Kingston in 2001. From 2007 until
2017, he was the Head of the Department of Psychiatry at Queen's
University. In 2017, he became the Director of Centre for
Neuroscience Studies at Queen's University and in 2018, he was
appointed as Vice President, Medical and Academic Affairs at
Providence Care Hospital. He is the current Executive Chair Elect of
the Canadian Network for Mood and Anxiety Treatments (CANMAT) and
an Executive Committee Member of the Canadian Biomarker Integration
Network for Depression (CAN-BIND). He is a Fellow of the Royal
College of Psychiatrists (UK), a Distinguished Fellow of both the
Canadian and American Psychiatry Associations, a Fellow of the
Royal College of Physicians of Canada and defended a PhD in
Forensic Psychiatry.
Dr. Milev is actively involved in
research in depression, bipolar disorder, and other mental
disorders with a strong focus on stigma, sleep architecture,
psychopharmacological and neurostimulation treatments as well as,
microbiome manipulation for treatment of mood and anxiety
disorders. He is the author and editor of over 140 peer-reviewed
articles and book chapters and has co-authored multiple CANMAT
guidelines for management of patients with Major Depressive
Disorder and Bipolar Disorders, the world's most cited mood
disorder treatment guidelines as well as CANMAT treatment
guidelines including ketamine and neurostimulation.
"Dr. Milev is a global expert in
research of novel treatments for mood and anxiety disorders and
brings unparalleled experience and leadership expertise in
interventional psychiatry which will help support the development
and integration of the most successful protocols and treatment
modalities for the launch of our specialty clinics. With the
addition of Dr. Milev to the clinics board, NeonMind will be well
positioned to deliver top notch medical services and programs,
bringing access to patients and communities in need," said Robert
Tessarolo, President & CEO of NeonMind.
On the importance of
interventional psychiatry, Dr. Milev said, "I am very proud of the
work our team at Providence Care is doing to have successfully set
up and operated our Interventional Psychiatry which is providing
important treatment services to patients using ketamine and
neurostimulation modalities. There are many opportunities to expand
patients' access to these highly effective and safe treatments. I
am pleased to be working with NeonMind in developing their network
of clinics that is focused on enhancing access to treatments and
bringing them into community healthcare."
About
NeonMind Biosciences Inc.
NeonMind operates two divisions:
(i) a pharmaceutical division engaged in drug development of
psychedelic compounds with two lead psilocybin-based drug
candidates targeting obesity; and (ii) a medical services division
focused on launching specialty mental health clinics that integrate
psychedelic therapeutics into traditional psychotherapy
settings.
In its pharmaceutical division,
NeonMind has two distinct psilocybin drug development programs
targeting obesity. NeonMind's lead candidate, NEO-001, employs
psilocybin as an agonist at the serotonin 5- HT2A receptor, which
is involved in the hallucinogenic effect of psychedelics. The
Company's second drug candidate, NEO-002, employs low-dose
psilocybin as an agonist at the 5-HT2C receptor, which controls
appetite.
NeonMind established a medical
services division with the goal of launching NeonMind-branded
specialty mental health clinics in Canada that incorporate
evidence-backed innovative treatments to address a variety of
mental health needs.
For more information on NeonMind,
go to www.NeonMindBiosciences.com
Rob Tessarolo,
President & Chief Executive Officer, NeonMind Biosciences
Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor
Relations:
KCSA Strategic
Communications
Scott Eckstein/Tim
Regan
neonmind@kcsa.com
Tel: 212-896-1210
Media
Inquiries:
KCSA Strategic
Communications
Annie Graf
neonmind@kcsa.com
Tel: 786-390-2644
The Canadian
Securities Exchange has not reviewed, approved nor disapproved the
contents of this news release.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or NeonMind's future performance. The use of any of the
words "could", "expect", "believe", "will", "projected",
"estimated" and similar expressions and statements relating to
matters that are not historical facts are intended to identify
forward-looking information and are based on NeonMind's current
belief or assumptions as to the outcome and timing of such future
events. Actual future results may differ materially. In particular,
NeonMind's drug development plans, its ability to retain key
personnel, and its expectation as to the development of its
intellectual property and other steps in its preclinical and
clinical drug development constitute forward-looking information.
Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned
not to place undue reliance on forward-looking information. The
statements made in this press release are made as of the date
hereof. NeonMind disclaims any intention or obligation to publicly
update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
may be expressly required by applicable securities laws.